Farjad Sarafian, MD, FIDSA

Fellowship, Infectious Diseases.

UCLA, Center for Health Sciences,

Division of Infectious Diseases

2005-2007

Internship and residency, Internal Medicine.

UCLA / Wadsworth VA Medical Center

Department of Internal Medicine

1998-2001

• 2024. Principle Investigator. ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension. Mannkind MKC-CI-002
• 2024. Sub-investigator. A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years. Janssen VAC52416BAC3001.
• 2024. Sub-investigator. RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).
• 2020, Sub-investigator. A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants with Severe COVID-19. Gilead GS-US-540-5773
• 2020, Sub-investigator, A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants with Moderate COVID-19. Gilead GS-US-540-5774
• 2020, Treating Physician. Expanded access to convalescent plasma for the treatment of patient with COVID-19. Mayo Clinic. 04338360
• 2020, Sub-investigator. A phase III, randomized, double-blind, multicenter study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with severe COVID-19 pneumonia. F. Hoffmann-La Roche Ltd. WA42511
• 2020, Sub-investigator. A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19. AstraZeneca D822FC00003
• 2020, Sub-investigator. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection. Lilly I4V-MC-KHAA:
• 2005-2007. Assessment of factors affecting adherence to highly active antiretroviral therapy (HAART) in different ethnicities in Multicenter AIDS Cohort Study (MACS).
• 1996-1998, Characteristic differences between leukocytosis caused by inflammation and that caused by stress or trauma., Shlomo Berliner, MD, PhD, Tel Aviv Sourasky Medical Center, Tel Aviv University.
• 1992-1993, Post-mortem quantification of Aluminum and Silicon levels in the chromatins of neurofibrillary tangles of Alzheimer patients., Edith Carlisle, PhD, University of California, Los Angeles.

• Remdesivir and Mortality in Patients with COVID-19, Diaz GA, Christensen AB, Pusch T, Goulet D, Chang SC, Grunkemeier GL, McKelvey PA, Robicsek A, French T, Parsons GT, Doherty G, Laurenson C, Roper R, Hadlock J, Cover CJ, Footer B, Robinson P, Micikas M, Marfori JE, Cronenweth C, Mukkamala Y, Mackiewicz J, Rai E, Matson MD, Davila J, Rueda J, Tipton R, Algren H, Ward BC, Malkoski S, Gluckman T, Tallman GB, Arguinchona H, Hammond TC, Standaert S, Christensen J, Echaiz JF, Choi R, McClung D, Pacifico A, Fee M, Sarafian F, Berrington WR, Goldman JD., Clin Infect Dis., 08/14/21, 34409431
• Clinical trial design during and beyond the pandemic: the I-SPY COVID trial., I-SPY COVID Consortium., Nat Med., 01/01/22, 28, 1, 9-11, 35058620
• Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial., ITAC (INSIGHT 013) Study Group., Lancet., 02/05/22, 399, 10324, 530-540, 35093205
• Evaluation of Adherence and Factors Affecting Adherence to Combination Antiretroviral Therapy among White, Hispanic, and Black Men in the MACS Cohort, Debora Lee Oh, Farjad Sarafian, Anthony Silvestre, Todd Brown, Lisa Jacobson, Sheila Badri, and Roger Detels., J Acquir Immune Defic Syndr., 10/01/09, 52, 2, 290, 35093205
• Stress in the emergency room: a simple leukocyte to glass adhesion test provides a diagnostic tool to differentiate between stress and infection/inflammation related leukocytosis., Gill Fier, MD, Farjad Sarafian, MD, Shlomo Berliner, MD, PhD, et al., Stress Medicine., 01/01/99, 15, 3, 183-188

• Board Certified in Infectious Diseases, ABIM
• Board Certified in Internal Medicine, ABIM
• Medical Board of California, License #A72530
• Qualified Medical Evaluator (QME), State of California
• Collaborative Institutional Training Initiative (CITI Program), Certified

• Hoag Memorial Hospital, Newport Beach, CA
• Mission Regional Medical Center, Mission Viejo, CA
• Saddleback Memorial Medical Center, Laguna Hills, CA

Fellow, Infectious Disease Society of America (IDSA)

Member, Infection prevention committee, Hoag Hospital, Newport Beach, CA

Member, Medicine Executive Committee, Mission Hospital, Mission Viejo, CA

Member, Medecins Sans Frontieres, France

Member, Doctors Without Borders, USA

Member, AMA

UCLA Association of Chemists and Biochemists